Trial reportCirculation journal : official journal of the Japanese Circulation Society2009
Incremental effects of eicosapentaenoic acid on cardiovascular events in statin-treated patients with coronary artery disease.
Trial report in Circulation journal : official journal of the Japanese Circulation Society, 2009. The graph read 4 numbers from its abstract, feeding 2 cells of the map: it supports the treatment in 2. Cited by 50 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
Among 1,050 patients with prior myocardial infarction (MI), the incidence of MCE in the EPA group (15.0%) was significantly lower than that in the control group (20.1%, adjusted hazard ratio =0.73, 95%CI 0.54-0.98, P=0.033, NNT =19).
Read, but not usablea number the graph found but could not read as for or against
The incidence of MCE was significantly lower in the EPA group (8.7% vs 10.7%, adjusted hazard ratio =0.77, 95% confidence interval (CI) 0.63-0.96, P=0.017, number needed to treat (NNT) =49).
Among 1,050 patients with prior myocardial infarction (MI), the incidence of MCE in the EPA group (15.0%) was significantly lower than that in the control group (20.1%, adjusted hazard ratio =0.73, 95%CI 0.54-0.98, P=0.033, NNT =19).
The incidence of MCE was significantly lower in the EPA group (8.7% vs 10.7%, adjusted hazard ratio =0.77, 95% confidence interval (CI) 0.63-0.96, P=0.017, number needed to treat (NNT) =49).
clause the extractor read what became the number
Where it lands on the map
Rows are treatments, columns are outcomes. The coloured squares are the cells this paper feeds, coloured by the vote it casts there. Click one to jump to what this paper adds to it.
What it adds to each cell
For every cell the paper feeds: the belief in the claim with and without this paper, and this paper's estimate drawn against every other readable study in the cell. The ringed dot is this paper.
Other lipid agents×cardiovascular events
SupportsOpen on the map →What to test next →10 readable studies in this cell: 5 favour the treatment, 5 find no difference, 0 favour the comparator.
Statins×cardiovascular events
SupportsOpen on the map →What to test next →29 readable studies in this cell: 17 favour the treatment, 11 find no difference, 1 favour the comparator.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 7 syntheses or guidelines pooled it, 154 citations in OpenAlex.
- Marine-derived n-3 fatty acids therapy for stroke.The Cochrane database of systematic reviews · 2022Pooled it
- Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease.The Cochrane database of systematic reviews · 2020Pooled it
- Marine-derived n-3 fatty acids therapy for stroke.The Cochrane database of systematic reviews · 2019Pooled it
- Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease.The Cochrane database of systematic reviews · 2018Pooled it
- Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease.The Cochrane database of systematic reviews · 2018Pooled it
- Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease.The Cochrane database of systematic reviews · 2018Pooled it
- Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease.The Cochrane database of systematic reviews · 2018Pooled it
- Effects of Food on the Pharmacokinetics of Omega-3-Carboxylic Acids in Healthy Japanese Male Subjects: A Phase I, Randomized, Open-label, Three-period, Crossover Trial.Journal of atherosclerosis and thrombosis · 2017Trial
- Statin treatment alters serum n-3 to n-6 polyunsaturated fatty acids ratio in patients with dyslipidemia.Lipids in health and disease · 2015Trial
- Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2022.Journal of atherosclerosis and thrombosis · 2024Article
- Cost-Effectiveness of Icosapent Ethyl for Ischemic Cardiovascular Events.The journal of Tehran Heart Center · 2024Article
- A promising drug for neuropathic pain: identification of vesicular nucleotide transporter as a novel target of eicosapentaenoic acid.Purinergic signalling · 2023Article
- Assessing Health and Economic Benefits of Omega-3 Fatty Acid Supplementation on Cardiovascular Disease in the Republic of Korea.Healthcare (Basel, Switzerland) · 2023Article
- Omega-3 Fatty Acids in Arterial Hypertension: Is There Any Good News?International journal of molecular sciences · 2023Review
- Deranged Myocardial Fatty Acid Metabolism in Heart Failure.International journal of molecular sciences · 2022Review
- Essential Polyunsaturated Fatty Acids in Blood from Patients with and without Catheter-Proven Coronary Artery Disease.International journal of molecular sciences · 2022Article
- Protective Effects of Eicosapentaenoic Acid on the Glomerular Endothelium via Inhibition of EndMT in Diabetes.Journal of diabetes research · 2021Article
- Prevention of Cardiovascular Events with Omega-3 Polyunsaturated Fatty Acids and the Mechanism Involved.Journal of atherosclerosis and thrombosis · 2020Review
- High-Dose Omega-3 Fatty Acids in Cardiovascular Prevention: Finally Living Up to Their Potential?American journal of cardiovascular drugs : drugs, devices, and other interventions · 2020Review
- Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
17 authors at 14 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The marked sentences are the ones the graph read a number from.
backgroundResults from JELIS (Japan EPA Lipid Intervention Study) demonstrated the efficacy of pure eicosapentaenoic acid (EPA) in preventing coronary artery disease (CAD) in hypercholesterolemic patients under statin treatment. The present study examined in detail whether EPA is effective for the secondary prevention of CAD. METHODS AND
resultsPatients with established CAD and a total cholesterol level > or =250 mg/dl were observed with a mean follow-up of 4.6 years. They were randomly assigned to receive either 1,800 mg of EPA + statin (EPA group) or statin alone (control group). The incidence of major coronary events (MCE) were compared in the 2 groups. The incidence of MCE was significantly lower in the EPA group (8.7% vs 10.7%, adjusted hazard ratio =0.77, 95% confidence interval (CI) 0.63-0.96, P=0.017, number needed to treat (NNT) =49). Among 1,050 patients with prior myocardial infarction (MI), the incidence of MCE in the EPA group (15.0%) was significantly lower than that in the control group (20.1%, adjusted hazard ratio =0.73, 95%CI 0.54-0.98, P=0.033, NNT =19).
conclusionsEPA is effective for secondary prevention of CAD, especially in individuals with prior MI, and should be added to conventional treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.